The potential candidate is the patient who, after stabilization, has persistent and cosmetically important loss with a transplantable diagnosis and an adequate, stable donor area
Wegovy, approved in 2021, has shown significant results in promoting weight loss, with clinical trial participants losing an average of 17-18% of their body weight over 68 weeks
The NHS does not recommend GLP-1 medications for thyroid conditions unless concurrent diabetes or obesity criteria are met
Pre-Authorize Your Card: We pre-authorize your card to ensure payment
1 Reconstitute using sterile bacteriostatic water
Rapid Rise in Compounding Pharmacies: More than 60% of the providers that have applied for LegitScript Healthcare Merchant Certification focus on weight-loss medication, and of those, 98% offer compounded GLP-1s